Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease.
about
Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative DiseasesMicroglia-Induced Maladaptive Plasticity Can Be Modulated by Neuropeptides In VivoNeuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugsNon-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium?Uncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/β-catenin signaling cascade as the common final pathway for neuroprotection and self-repairMicroglial priming and enhanced reactivity to secondary insult in aging, and traumatic CNS injury, and neurodegenerative diseaseOral microbiome link to neurodegeneration in glaucomaSigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neuronsParkinson's disease and immune system: is the culprit LRRKing in the periphery?Banking on iPSC--is it doable and is it worthwhileStem cell therapy for central nerve system injuries: glial cells hold the keyDelirium and high fever are associated with subacute motor deterioration in Parkinson disease: a nested case-control studySystemic inflammation and disease progression in Alzheimer disease.Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease.Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice.Voluntary exercise reduces the neurotoxic effects of 6-hydroxydopamine in maternally separated ratsInterleukin-1beta-induced brain injury and neurobehavioral dysfunctions in juvenile rats can be attenuated by alpha-phenyl-n-tert-butyl-nitrone.Evidence of inflammatory system involvement in Parkinson's disease.Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia.Interleukin-1 receptor antagonist ameliorates neonatal lipopolysaccharide-induced long-lasting hyperalgesia in the adult ratsSystemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration.Dopaminergic neuronal injury in the adult rat brain following neonatal exposure to lipopolysaccharide and the silent neurotoxicity.The endotoxin-induced neuroinflammation model of Parkinson's disease.Exacerbation of CNS inflammation and neurodegeneration by systemic LPS treatment is independent of circulating IL-1β and IL-6.IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's diseaseStatins and brain dysfunction: a hypothesis to reduce the burden of cognitive impairment in patients who are critically illNeonatal exposure to lipopolysaccharide enhances vulnerability of nigrostriatal dopaminergic neurons to rotenone neurotoxicity in later life.Interleukin-1 receptor antagonist reduces neonatal lipopolysaccharide-induced long-lasting neurobehavioral deficits and dopaminergic neuronal injury in adult rats.The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation.Astrocytes Are Primed by Chronic Neurodegeneration to Produce Exaggerated Chemokine and Cell Infiltration Responses to Acute Stimulation with the Cytokines IL-1β and TNF-α.Glucocorticoid-induced leucine zipper (GILZ) over-expression in T lymphocytes inhibits inflammation and tissue damage in spinal cord injury.Baseline Plasma C-Reactive Protein Concentrations and Motor Prognosis in Parkinson DiseaseAn Effective Method to Identify Shared Pathways and Common Factors among Neurodegenerative DiseasesSystemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegenerationAugmentation of Autoantibodies by Helicobacter pylori in Parkinson's Disease Patients May Be Linked to Greater SeverityPeripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseasesIL-1 signal affects both protection and pathogenesis of virus-induced chronic CNS demyelinating disease.Pathogenesis of cognitive dysfunction in patients with obstructive sleep apnea: a hypothesis with emphasis on the nucleus tractus solitariusMagnetic resonance imaging reveals therapeutic effects of interferon-beta on cytokine-induced reactivation of rat model of multiple sclerosisSystemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease.
P2860
Q26779933-9029D5EA-E902-4DB2-852D-5691B228DF96Q26798185-90074B80-0F0A-4230-837B-90410898F5E3Q26801035-BD290E4A-A83D-4ABE-A7FA-DBFE39EC47BEQ26822022-25B9EA7F-54DB-4227-9AB9-42918E325C8CQ26865502-9BF63CCA-1890-4959-BA52-19F238AE1705Q27026599-FC00D32B-752E-4467-A245-F093CA73DAAEQ27316016-589BF9A7-644C-4852-8F6A-C8568ECBD6BFQ27330088-9A3F4A9A-A808-43C0-82DB-E0A80F40A2F8Q27687171-467A2836-CF44-4981-B8AA-685BAEB643FDQ28254023-918AAE8A-9865-4CEF-9107-9B83ACF5EAD3Q28394140-18518F89-4578-42FD-A33F-A0DAF50F76A1Q33699840-BD519723-DF65-4D46-A85D-273E5E920E53Q33765718-B43AAE78-BC90-4FD9-B049-F9673E4C4CC1Q33771694-96FA8EB4-DE48-4010-A8C0-6C8DD7B76934Q33797938-73EBE083-7C1D-4E38-9583-92789E7E456CQ33820619-F42234EB-DEB5-47ED-BE23-68116A30B158Q33862623-F933EB2B-1398-4F6C-AAC8-5324D1DBDFC9Q33890818-6741F29D-0F00-4324-A497-13B9262E0EE0Q34230271-D0F28767-FB43-456E-9163-BC8B899FC188Q34414263-004BFD66-E71E-470D-9B6C-0CF5D139E8CEQ34463760-75297A86-C1A3-41A3-8744-6A9491F02C98Q34510971-ABEF5498-B8EF-4E77-90A1-9EFF08019B68Q34557246-26885F6B-D82B-49DC-9A3F-E563A26434ACQ35057271-6784153F-2F79-442C-8F9A-E3AC418CE6B8Q35064839-B067C41C-DD49-4D15-A664-F18B52B8FCC5Q35201872-A3C41B99-E53E-44CC-8BFA-7260006D1F10Q35255816-2410BAA3-572E-4D96-ADDA-5D09865249EAQ35585714-E6EAE8D0-5350-4E29-BFC2-045B20FD3361Q35617879-379DE47B-1B72-4687-9980-564B925D6DD4Q35675181-1BCEC93A-D561-4A29-A741-0046BDE1CD90Q35729623-33745C57-16AC-48ED-9C4C-7D5A7582CCF3Q35755849-E5C90DAA-4B12-4795-9A90-BA3EEA410B6FQ35843631-8BC684FA-C2C8-4B7B-A3D1-D8A6696DF6F3Q35906528-98B8DACA-4416-4934-A5E1-C1C73717DBFFQ35995995-FD6D17ED-91EE-408C-9F58-09696E1BBD6CQ36023238-781A196D-98BD-48E9-98C5-87128502EF91Q36292874-11C4520C-6B62-4565-ACE1-9D352E7858EEQ36635045-53812977-426C-43B6-9923-5A8E4B7EE7E4Q36839991-FB8F432C-0825-4C5B-A1BA-C76F59A4F5D2Q37078772-6A1BF857-9877-4619-8CD1-FC65EAAE56EA
P2860
Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Central and systemic IL-1 exac ...... model of Parkinson's disease.
@ast
Central and systemic IL-1 exac ...... model of Parkinson's disease.
@en
type
label
Central and systemic IL-1 exac ...... model of Parkinson's disease.
@ast
Central and systemic IL-1 exac ...... model of Parkinson's disease.
@en
prefLabel
Central and systemic IL-1 exac ...... model of Parkinson's disease.
@ast
Central and systemic IL-1 exac ...... model of Parkinson's disease.
@en
P2860
P50
P356
P1433
P1476
Central and systemic IL-1 exac ...... model of Parkinson's disease.
@en
P2860
P304
P356
10.1093/BRAIN/AWN101
P4011
37ce2b27f9835fb917fb87872a1ad3547edbab10
P407
P577
2008-05-26T00:00:00Z